Markus Cappel Biography and Net Worth

Treasurer of ChemoCentryx

Dr. Markus J. Cappel Ph.D. serves as Chief Business Officer, Treasurer of the Company. From March 2003 to February 2007, he served as our Senior Vice President of Corporate and Business Development. From October 2001 to March 2003, Dr. Cappel served as our Vice President of Business Development. Prior to joining us, Dr. Cappel served as Vice President of Business Development at Alkermes, Inc., a biotechnology company, from 1998 to 2001. Prior to this, he served as Director of Business Development with Millennium Pharmaceuticals as well as in various business development roles at Cygnus, Inc., a biotechnology company. Dr. Cappel received his B.S. in pharmacy and his Ph.D. in pharmaceutics from J.W. Goethe University, Frankfurt, Germany, and his M.B.A. from Harvard Business School. Dr. Cappel also completed postdoctoral studies in pharmaceutics at the University of Michigan.

What is Markus J. Cappel's net worth?: The estimated net worth of Markus J. Cappel is at least $4.56 million as of August 4th, 2022. Dr. Cappel owns 87,658 shares of ChemoCentryx stock worth more than $4,557,339 as of April 4th. This net worth estimate does not reflect any other assets that Dr. Cappel may own. Additionally, Dr. Cappel receives a salary of $643,580.00 as Treasurer at ChemoCentryx. Learn More about Markus J. Cappel's net worth.
How old is Markus J. Cappel?: Dr. Cappel is currently 61 years old. There are 5 older executives and no younger executives at ChemoCentryx. The oldest executive at ChemoCentryx is Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman, who is 63 years old. Learn More on Markus J. Cappel's age.
What is Markus J. Cappel's salary?: As the Treasurer of ChemoCentryx, Inc., Dr. Cappel earns $643,580.00 per year. There are 4 executives that earn more than Dr. Cappel. The highest earning executive at ChemoCentryx is Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman, who commands a salary of $1,210,000.00 per year. Learn More on Markus J. Cappel's salary.
How do I contact Markus J. Cappel?: The corporate mailing address for Dr. Cappel and other ChemoCentryx executives is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. ChemoCentryx can also be reached via phone at (650) 210-2900 and via email at investor@chemocentryx.com. Learn More on Markus J. Cappel's contact information.
Has Markus J. Cappel been buying or selling shares of ChemoCentryx?: Markus J. Cappel has not been actively trading shares of ChemoCentryx over the course of the past ninety days. Most recently, Markus J. Cappel sold 7,564 shares of the business's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $50.22, for a transaction totalling $379,864.08. Following the completion of the sale, the treasurer now directly owns 87,658 shares of the company's stock, valued at $4,402,184.76. Learn More on Markus J. Cappel's trading history.
Who are ChemoCentryx's active insiders?: ChemoCentryx's insider roster includes Tausif Butt (COO), Markus Cappel (Treasurer), Thomas Edwards (Director), Susan Kanaya (CFO), Geoffrey Parker (Director), Thomas Schall (CEO), and James Tyree (Director). Learn More on ChemoCentryx's active insiders.

Markus J. Cappel Insider Trading History at ChemoCentryx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/4/2022	Sell	7,564	$50.22	$379,864.08	87,658
3/1/2021	Sell	33,092	$68.43	$2,264,485.56	91,243
2/8/2021	Sell	9,625	$67.26	$647,377.50	87,226
2/5/2021	Sell	805	$67.07	$53,991.35	87,226
1/25/2021	Sell	1,375	$67.03	$92,166.25	87,201
6/12/2020	Sell	33,541	$65.10	$2,183,519.10	109,788
5/26/2020	Sell	19,612	$60.34	$1,183,388.08	79,047
5/22/2020	Sell	40,867	$60.06	$2,454,472.02	79,047
5/11/2020	Sell	34,222	$55.11	$1,885,974.42	80,559
5/8/2020	Sell	4,312	$50.01	$215,643.12	80,559
5/5/2020	Sell	8,860	$55.01	$487,388.60	85,107
2/19/2020	Sell	42,631	$50.36	$2,146,897.16	118,878
2/6/2020	Sell	36,850	$47.31	$1,743,373.50	113,097
1/21/2020	Sell	1,259	$44.00	$55,396.00	77,506
1/16/2020	Sell	50,000	$40.07	$2,003,500.00	126,247
1/13/2020	Sell	86,311	$37.09	$3,201,274.99	162,558
11/26/2019	Sell	330,524	$32.03	$10,586,683.72	99,764
1/9/2019	Sell	8,134	$12.00	$97,608.00	40,510
1/7/2019	Sell	5,069	$12.07	$61,182.83	40,510
10/26/2018	Sell	30,237	$11.01	$332,909.37	54,063
6/29/2018	Sell	25,179	$13.67	$344,196.93	24,626
6/27/2018	Sell	800	$13.50	$10,800.00	24,626
5/21/2018	Sell	2,709	$13.00	$35,217.00	26,535
5/16/2018	Sell	50,000	$11.81	$590,500.00	40,492
5/2/2018	Sell	50,000	$11.02	$551,000.00	35,737
1/3/2017	Sell	26,821	$7.51	$201,425.71	20,833
3/9/2015	Sell	34,125	$7.81	$266,516.25
3/4/2015	Sell	40,875	$7.98	$326,182.50
3/3/2015	Sell	5,943	$7.81	$46,414.83
3/2/2015	Sell	14,390	$8.13	$116,990.70
4/22/2014	Sell	20,962	$8.17	$171,259.54
8/13/2013	Sell	5,459	$12.90	$70,421.10
8/1/2013	Sell	6,250	$13.82	$86,375.00
7/17/2013	Sell	5,459	$14.52	$79,264.68
7/2/2013	Sell	6,250	$13.88	$86,750.00
6/21/2013	Sell	6,250	$13.00	$81,250.00
6/18/2013	Sell	1,783	$12.47	$22,234.01
5/28/2013	Sell	3,676	$14.10	$51,831.60
5/15/2013	Sell	15,668	$14.08	$220,605.44
4/11/2013	Sell	1,500	$14.10	$21,150.00
1/17/2013	Sell	2,700	$11.16	$30,132.00

See Full Table

Markus J. Cappel Buying and Selling Activity at ChemoCentryx

ChemoCentryx Company Overview

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Today's Range

Now: $51.99

$51.99

50 Day Range

MA: $51.95

$51.66

$51.99

2 Week Range

Now: $51.99

$14.95

$52.00

Volume

113 shs

Average Volume

1,681,906 shs

Market Capitalization

$3.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Markus Cappel Biography and Net Worth

What is Markus J. Cappel's net worth?

How old is Markus J. Cappel?

What is Markus J. Cappel's salary?

How do I contact Markus J. Cappel?

Has Markus J. Cappel been buying or selling shares of ChemoCentryx?

Who are ChemoCentryx's active insiders?